In order to access this content you must be logged in and have a subscription to PL Intelligence.

PL Intelligence is a one-stop environment for time-conscious executives. Keeping you abreast of the latest developments in the life sciences industry, saving you time and money when you need it most.
Xenon and Novartis Sign Drug Development Deal for Obesity and Metabolic Disorders
Xenon Genetics Awarded $4.7 million in Funding from Genome Canada and Genome BC
Xenon acquires lipid metabolism drug discovery program
CV Therapeutics Establishes Tangier Drug Discovery Program
TorreyPines Therapeutics Sells Alzheimer’s Disease Genetics Program to Eisai
Xenon Genetics and RGS Genome to merge
Xenon Genetics and Warner-Lambert agree cholesterol collaboration
NewLink Genetics selects Pyxis Discovery and ZoBio for fragment based drug discovery